Cellyan Biotechnology Co Ltd (HKPD) Stock Analysis
Verdict: AVOID
Severe cash burn leaves 3.4 months of runway, forcing dilutive financing that dominates micro-cap risk despite low P/S valuation.
Investment score: 25/100
Analysis as of
Is Cellyan Biotechnology Co Ltd stock worth reviewing? AI model thesis
The AI model advises avoiding HKPD due to severe financial distress, imminent cash depletion (~3.4 months runway), and aggressive share dilution.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Cellyan Biotechnology Co Ltd opportunities and risks
What speaks for HKPD
- Valuation upside if operational stabilization occurs
What speaks against HKPD
- Imminent cash exhaustion and severe equity dilution
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| HKPD | n/a | 0.1x | n/a | 10.3% | -8.5% | -39.5% |
| PSIG | n/a | 0.1x | 0.0x | 1.6% | -28.6% | -91.0% |
| PSIG | n/a | 0.1x | 0.0x | 1.6% | -28.6% | -91.0% |
| Peer median | n/a | 0.1x | 0.0x | 1.6% | -28.6% | -91.0% |
Frequently asked questions about Cellyan Biotechnology Co Ltd (HKPD)
Is HKPD stock a good investment?
The cached TradeMates AI model rates Cellyan Biotechnology Co Ltd as AVOID with an investment score of 25/100. The AI model advises avoiding HKPD due to severe financial distress, imminent cash depletion (~3.4 months runway), and aggressive share dilution. This is algorithmic model output, not personal investment advice.
Is HKPD stock a buy?
The TradeMates model verdict for HKPD is AVOID with an investment score of 25/100. Treat this as a model signal to review, not a personal buy recommendation.